Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
An Open-Label, Single-Arm, Dose-Exploration Study to Evaluate the Safety, Tolerability,
Preliminary Efficacy and Pharmacokinetics of CT048 in Subjects with Advanced Solid Tumors